Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 4/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376250 | 0.94 | CTSL (0.51) | KLKB1GAARAB9ACTSLCTSS | |
| SCHEMBL4367199 | 0.91 | CTSL (0.48) | KLKB1GAARAB9ACTSLCTSS | |
| SCHEMBL4368539 | 0.90 | KLKB1 (0.51) | KLKB1GAARAB9AL3MBTL1PLG | |
| SCHEMBL13620366 | 0.90 | CTSS (0.54) | KLKB1RAB9ACTSLCTSSL3MBTL1 | |
| SCHEMBL4361645 | 0.89 | CTSL (0.48) | KLKB1CTSLCTSSL3MBTL1PLG | |
| SCHEMBL4370281 | 0.89 | CTSS (0.50) | KLKB1CTSLCTSSL3MBTL1PLG | |
| SCHEMBL4376004 | 0.89 | CTSS (0.50) | KLKB1CTSLCTSSL3MBTL1PLG | |
| SCHEMBL4372754 | 0.89 | PLG (0.52) | KLKB1CTSLCTSSPLGPRSS1 | |
| SCHEMBL4369015 | 0.89 | PLG (0.52) | KLKB1CTSLCTSSPLGPRSS1 | |
| SCHEMBL4368444 | 0.88 | KLKB1 (0.53) | KLKB1CTSLCTSSPLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908466-B1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2014-02-19 | — | — | EP | disclosed |
| EP-1908466-B1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | KLKB1 3853/4885GAA 496/4885RAB9A 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.